Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.72 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)2.46M
Market Cap
$785.41M
Enterprise Value$1.18B
Total Cash (Recent Filing)$163.69M
Total Debt (Recent Filing)$411.76M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 11, 2025EPS Estimate
0.02Last Dividend Ex-Date
Dec 17, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding129,178,620
10 Day Avg. Volume3,393,231
30 Day Avg. Volume2,464,653
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit3.91
Enterprise Value/Ebitda-24.41
Forecast
1Y Price Target
$8.81Price Target Upside42.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceUnderlying clinical performance was solid in the quarter, and sequential AUP improvement was strong.
Core Clinical RevenueCore clinical revenues beat expectations, and any PanTracer contribution leaves room for upside.
Bears Say
Delayed Product LaunchA delay in the commercial launch of PanTracer™ Liquid Biopsy impacted the expected NGS revenue ramp.
Guidance CutNEO shares are down due to a larger than expected guidance cut for FY25.
Non-Clinical SegmentTotal revenue missed guidance and consensus due entirely to further headwinds in the 'non-clinical' business.
NeoGenomics News
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $4.72 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $785.41M.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Nov 11, 2025 which is in 87 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 29, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.023 by $0.007.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics dividends here
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.02.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 129,178,620 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.03 in its last earnings report, beating expectations of $0.023. Following the earnings report the stock price went down -18.731%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.81 (42.10% Upside)
$8.81 (42.10% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 131.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $250.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.13%
12-Months-Change
Fundamentals
Return on Equity
-11.76%
Trailing 12-Months
Asset Growth
-15.17%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a leading provider of cancer-focused genetic testing and diagnostic services. The company operates primarily in the healthcare sector, specializing in advanced genomic testing for oncology. NeoGenomics offers a comprehensive range of services, including molecular testing, hematopathology, and clinical trial services, aimed at improving cancer patient outcomes through precise and personalized treatment options.
NEO Company Deck
NEO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong clinical revenue growth and promising NGS performance, but these were overshadowed by significant declines in pharma services revenue, delays in product launches, and ongoing legal and market challenges. The sentiment is cautious as the company focuses on addressing these issues and realigning its strategy.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$8.81
▲(42.10% Upside)
Technical Analysis
Ownership Overview
1.20% Insiders
35.59% Mutual Funds
0.76% Other Institutional Investors
37.09% Public Companies and
Individual Investors